You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》高盛下調石藥(01093.HK)目標價至9.28元 評級「買入」
阿思達克 08-25 10:22
高盛發表報告指,石藥(01093.HK)第二季度的銷售及純利都符合該行預期,在藥品帶量採購下,抗腫瘤藥銷售下跌,但神經系統藥銷售改善的情況較預期佳,另外新冠疫情後病人流量恢復,零售渠道擴充,亦有助銷量提升。 報告指,管理層認為,近日醫藥反貪腐措施,對行業可能有短期影響,但公司維持指引,估計全年銷售額有正面增長。第二季度銷售開支佔比下跌,該行估計下半年持續改善。 該行將2023至2025年三年的盈利預測,分別下調1.2%、0.9%及1.6%,預期反貪腐措施的負面影響,部分被節省銷售成本所抵銷,目標價由10.18元下調至9.28元,評級「買入」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account